CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. CymaBay is developing seladelpar, a potent, selective, orally active PPARδ agonist for patients with primary biliary cholangitis (PBC). Seladelpar has received an orphan designation from the US Food and Drug administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA for early stage PBC and PRIority MEdicines status from the EMA. CymaBay is currently commencing a global, Phase 3 registration study of seladelpar for PBC. This study is a 52-week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelpar (RESPONSE) in patients with PBC.
Company profile
Ticker
CBAY
Exchange
Website
CEO
Sujal Shah
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
METABOLEX INC, METABOLEX, INC.
SEC CIK
Corporate docs
Subsidiaries
Which Incorporated • CymaBay UK, Ltd. • CymaBay Ireland, Limited • CymaBay Canada, Ltd. ...
CBAY stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Departure of Directors or Certain Officers
9 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
19 Apr 23
DEF 14A
Definitive proxy
19 Apr 23
S-3ASR
Automatic shelf registration
23 Mar 23
S-8
Registration of securities for employees
23 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Provides Corporate Update
16 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
Transcripts
CBAY
Earnings call transcript
2023 Q1
15 May 23
CBAY
Earnings call transcript
2022 Q4
16 Mar 23
CBAY
Earnings call transcript
2022 Q3
14 Nov 22
CBAY
Earnings call transcript
2022 Q2
12 Aug 22
CBAY
Earnings call transcript
2022 Q1
13 May 22
CBAY
Earnings call transcript
2021 Q4
18 Mar 22
CBAY
Earnings call transcript
2021 Q3
11 Nov 21
CBAY
Earnings call transcript
2021 Q2
13 Aug 21
CBAY
Earnings call transcript
2021 Q1
14 May 21
CBAY
Earnings call transcript
2020 Q4
26 Mar 21
Latest ownership filings
4
Harish Shantharam
22 May 23
3
Harish Shantharam
22 May 23
4
Charles McWherter
19 May 23
144
Notice of proposed sale of securities
18 May 23
4
Paul T Quinlan
17 May 23
144
Notice of proposed sale of securities
15 May 23
4
DENNIS D KIM
17 Apr 23
4
DENNIS D KIM
30 Mar 23
SC 13G
PERCEPTIVE ADVISORS LLC
10 Mar 23
SC 13G/A
TCG Crossover GP I, LLC
14 Feb 23
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 59.15 mm | 59.15 mm | 59.15 mm | 59.15 mm | 59.15 mm | 59.15 mm |
| Cash burn (monthly) | (no burn) | 1.24 mm | 8.96 mm | 7.96 mm | (no burn) | 4.36 mm |
| Cash used (since last report) | n/a | 2.46 mm | 17.80 mm | 15.81 mm | n/a | 8.66 mm |
| Cash remaining | n/a | 56.69 mm | 41.35 mm | 43.34 mm | n/a | 50.49 mm |
| Runway (months of cash) | n/a | 45.8 | 4.6 | 5.4 | n/a | 11.6 |
Institutional ownership, Q4 2022
81.3% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 124 |
| Opened positions | 29 |
| Closed positions | 9 |
| Increased positions | 30 |
| Reduced positions | 28 |
| 13F shares | Current |
|---|---|
| Total value | 385.11 bn |
| Total shares | 79.32 mm |
| Total puts | 222.20 k |
| Total calls | 374.90 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Avoro Capital Advisors | 10.30 mm | $64.58 bn |
| TCG Crossover GP I | 5.91 mm | $0.00 |
| TCG Crossover Management | 5.91 mm | $37.03 bn |
| Commodore Capital | 5.74 mm | $35.60 bn |
| Vanguard | 3.68 mm | $23.04 bn |
| Integrated Core Strategies | 2.99 mm | $5.87 mm |
| Nantahala Capital Management | 2.25 mm | $14.11 bn |
| Baker Bros. Advisors | 2.17 mm | $13.61 bn |
| Engine Capital | 2.10 mm | $8.77 mm |
| BLK Blackrock | 2.02 mm | $12.64 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 May 23 | Harish Shantharam | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 8.76 | 360,000 | 3.15 mm | 360,000 |
| 18 May 23 | McWherter Charles | Common Stock | Sell | Dispose S | No | Yes | 9.0757 | 21,749 | 197.39 k | 15,000 |
| 18 May 23 | McWherter Charles | Common Stock | Option exercise | Acquire M | No | No | 5 | 21,749 | 108.75 k | 36,749 |
| 18 May 23 | McWherter Charles | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 5 | 6,506 | 32.53 k | 45,540 |
| 18 May 23 | McWherter Charles | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 5 | 3,892 | 19.46 k | 27,242 |
| 18 May 23 | McWherter Charles | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 5 | 236 | 1.18 k | 1,650 |
| 18 May 23 | McWherter Charles | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 5 | 708 | 3.54 k | 4,952 |
| 18 May 23 | McWherter Charles | Employee Stock Option Common Stock | Option exercise | Dispose M | No | No | 5 | 10,407 | 52.04 k | 52,023 |
| 15 May 23 | Paul T Quinlan | Common Stock | Sell | Dispose S | No | Yes | 10.3662 | 5,000 | 51.83 k | 0 |
| 15 May 23 | Paul T Quinlan | Common Stock | Option exercise | Acquire M | No | No | 2.94 | 5,000 | 14.70 k | 5,000 |
News
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
22 May 23
Oppenheimer Maintains Outperform on CymaBay Therapeutics, Raises Price Target to $16
16 May 23
Expert Ratings for CymaBay Therapeutics
16 May 23
Cantor Fitzgerald Maintains Overweight on CymaBay Therapeutics, Raises Price Target to $15
16 May 23
HC Wainwright & Co. Reiterates Buy on CymaBay Therapeutics, Maintains $12 Price Target
16 May 23
Press releases
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
15 May 23
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
10 May 23
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
21 Apr 23
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
17 Apr 23
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
16 Mar 23